Spero Therapeutics (NASDAQ:SPRO) Insider Sells $63,352.40 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 25,240 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $2.51, for a total transaction of $63,352.40. Following the transaction, the insider directly owned 986,851 shares in the company, valued at approximately $2,476,996.01. The trade was a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Esther Rajavelu also recently made the following trade(s):

• On Friday, February 6th, Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12.

Spero Therapeutics Trading Up 2.0%

Spero Therapeutics stock opened at $2.56 on Friday. The stock has a market cap of $148.22 million, a price-to-earnings ratio of 21.34 and a beta of 1.43. The company’s 50-day moving average price is $2.51 and its two-hundred day moving average price is $2.41. Spero Therapeutics, Inc. has a 52 week low of $0.57 and a 52 week high of $3.22.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, March 26th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.73. The firm had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $26.00 million. Spero Therapeutics had a net margin of 12.83% and a return on equity of 22.53%.

Hedge Funds Weigh In On Spero Therapeutics

Large investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new position in shares of Spero Therapeutics during the 4th quarter valued at about $278,000. OMERS ADMINISTRATION Corp bought a new position in shares of Spero Therapeutics during the 4th quarter valued at about $306,000. State Street Corp boosted its position in shares of Spero Therapeutics by 10.1% during the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after purchasing an additional 19,200 shares in the last quarter. Shay Capital LLC bought a new position in shares of Spero Therapeutics during the 3rd quarter valued at about $120,000. Finally, Two Sigma Investments LP bought a new position in shares of Spero Therapeutics during the 3rd quarter valued at about $93,000. Institutional investors own 25.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on SPRO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Sunday, March 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.